

World Journal of *Gastroenterology*

World J Gastroenterol 2022 January 14; 28(2): 176-274



Contents

Weekly Volume 28 Number 2 January 14, 2022

REVIEW

- 176 Nanotheranostics: A powerful next-generation solution to tackle hepatocellular carcinoma
Ladju RB, Ulhaq ZS, Soraya GV

MINIREVIEWS

- 188 Multiple subcellular localizations and functions of protein kinase C δ in liver cancer
Yamada K, Yoshida K
- 199 Therapeutic endoscopy for the treatment of post-bariatric surgery complications
Larsen M, Kozarek R
- 216 Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma
Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, Lau DTY

ORIGINAL ARTICLE

Case Control Study

- 230 Obesity is associated with decreased risk of microscopic colitis in women
Sandler RS, Keku TO, Woosley JT, Sandler DP, Galanko JA, Peery AF

Observational Study

- 242 Identification of functional tumor necrosis factor-alpha promoter variants associated with *Helicobacter pylori* infection in the Sudanese population: Computational approach
Idris AB, Idris AB, Gumaa MA, Idris MB, Elgoraish A, Mansour M, Allam D, Arbab BM, Beirag N, Ibrahim EAM, Hassan MA

Prospective Study

- 263 Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison
Chen CT, Lu MY, Hsieh MH, Tsai PC, Hsieh TY, Yeh ML, Huang CI, Tsai YS, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Huang CF, Huang JF, Dai CY, Chuang WL, Shih YL, Yu ML

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Raffaele Iorio, MD, Associate Professor of Pediatrics, Department of Translational Medical Science, University of Naples Federico II, via S. Pansini n. 5, Napoli 80131, Italy. riorio@unina.it

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Report® cites the 2020 impact factor (IF) for WJG as 5.742; Journal Citation Indicator: 0.79; IF without journal self cites: 5.590; 5-year IF: 5.044; Ranking: 28 among 92 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2020 is 6.9 and Scopus CiteScore rank 2020: Gastroenterology is 19/136.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yin, Production Department Director: Xu Guo, Editorial Office Director: Ze-Mao Gong.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

January 14, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Case Control Study

Obesity is associated with decreased risk of microscopic colitis in women

Robert S Sandler, Temitope O Keku, John T Woosley, Dale P Sandler, Joseph A Galanko, Anne F Peery

ORCID number: Robert S Sandler 0000-0002-1323-6245; Temitope O Keku 0000-0003-4019-3903; John T Woosley 0000-0001-5876-3068; Dale P Sandler 0000-0002-6776-0018; Joseph A Galanko 0000-0003-2304-4375; Anne F Peery 0000-0002-2005-0780.

Author contributions: Sandler RS and Keku TO designed the research and obtained funding; Sandler RS, Keku TO and Woosley JT acquired the data; Sandler RS, Keku TO, Woosley JT, Galanko JA, Sandler DP and Peery AF analyzed and interpreted the data and wrote the paper.

Institutional review board statement: The study was approved by the University of North Carolina Office of Human Research Ethics. All patients gave informed consent.

Conflict-of-interest statement: Disclosures: None of the authors have financial, professional or personal conflicts of interest.

Data sharing statement: Data will not be available to other researchers.

STROBE statement: The authors have read the STROBE Statement - checklist of items, and the manuscript was prepared and

Robert S Sandler, Department of Medicine, University of North Carolina, Chapel Hill, NC 27514-7555, United States. rsandler@med.unc.edu

Temitope O Keku, Joseph A Galanko, Anne F Peery, Department of Medicine, University of North Carolina, Chapel Hill, NC 27514-7555, United States

John T Woosley, Department of Pathology, University of North Carolina, Chapel Hill, NC 27514, United States

Dale P Sandler, Department of Health and Human Services, National Institute of Environmental Health Sciences, Durham, NC 27709, United States

Corresponding author: Robert S Sandler, MD, MPH, Professor, Department of Medicine, University of North Carolina, No. 130 Mason Farm Road, Chapel Hill, NC 27599-7555, United States. rsandler@med.unc.edu

Abstract

BACKGROUND

Microscopic colitis is a leading cause of diarrhea in the older adults. There is limited information about risk factors. We hypothesized that obesity would be associated with microscopic colitis.

AIM

To examine the association between obesity and microscopic colitis in men and women undergoing colonoscopy.

METHODS

We conducted a case-control study at the University of North Carolina Hospitals. We identified and enrolled men and women referred for elective, outpatient colonoscopy for chronic diarrhea. We excluded patients with a past diagnosis of Crohn's disease or ulcerative colitis. A research pathologist reviewed biopsies on every patient and classified them as microscopic colitis cases or non-microscopic colitis controls. Patients provided information on body weight, height and exposure to medications *via* structured interviews or Internet based forms. The analysis included 110 patients with microscopic colitis (cases) and 252 non-microscopic colitis controls. Multivariable analyses were performed using logistic regression to estimate odds ratios and 95% confidence intervals.

revised according to the STROBE Statement—checklist of items.

Supported by the National Institutes of Health, No. P30 DK034987 and No. R01 DK105114.

Country/Territory of origin: United States

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C, C, C, C
Grade D (Fair): 0
Grade E (Poor): 0

Received: September 12, 2021

Peer-review started: September 12, 2021

First decision: October 16, 2021

Revised: October 18, 2021

Accepted: December 31, 2021

Article in press: December 31, 2021

Published online: January 14, 2022

P-Reviewer: Ding L, Nakaji K, Zhou Y

S-Editor: Wang LL

L-Editor: A

P-Editor: Wang LL



RESULTS

Cases were older and more likely than controls to be white race. Study subjects were well educated, but cases were better educated than controls. Cases with microscopic colitis had lower body mass index than controls and reported more weight loss after the onset of diarrhea. Compared to patients who were normal or under-weight, obese (BMI > 30 kg/m²) patients were substantially less likely to have microscopic colitis after adjusting for age and education, adjusted OR (aOR) 0.35, 95% confidence interval (CI) 0.18-0.66). When stratified by sex, the association was limited to obese women, aOR 0.21, 95%CI: 0.10-0.45. Patients with microscopic colitis were more likely to report weight loss after the onset of diarrhea. After stratifying by weight loss, there remained a strong inverse association between obesity and microscopic colitis, aOR 0.33, 95%CI: 0.10 – 1.11 among the patients who did not lose weight. Ever use of birth control pills was associated with lower risk of microscopic colitis after adjusting for age, education and BMI, aOR 0.38, 95%CI: 0.17-0.84.

CONCLUSION

Compared to controls also seen for diarrhea, microscopic colitis cases were less likely to be obese. Mechanisms are unknown but could involve hormonal effects of obesity or the gut microbiome.

Key Words: Colitis; Microscopic/epidemiology; Humans; Diarrhea/epidemiology; Obesity

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: We conducted a case control study among patients undergoing colonoscopy for diarrhea. The analysis included 110 patients with microscopic colitis and 252 controls. Obesity was associated with a substantially lower risk of microscopic colitis among women that was not explained by weight loss following the onset of diarrhea. Ever use of birth control pills was associated with lower risk of microscopic colitis after adjusting for age, education and BMI. The mechanism could involve hormonal effects of obesity or the gut microbiome.

Citation: Sandler RS, Keku TO, Woosley JT, Sandler DP, Galanko JA, Peery AF. Obesity is associated with decreased risk of microscopic colitis in women. *World J Gastroenterol* 2022; 28(2): 230-241

URL: <https://www.wjgnet.com/1007-9327/full/v28/i2/230.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v28.i2.230>

INTRODUCTION

Microscopic colitis is a chronic inflammatory disease of the colon characterized by a normal or near normal endoscopic appearance but abnormal pathology. It is increasingly recognized that endoscopically visible lesions can be recognized in nearly 40% of patients although they are non-specific[1]. Histologically, there is a thickened collagen band (collagenous colitis) or an increase in intraepithelial lymphocytes (lymphocytic colitis)[1]. Microscopic colitis was first described in 1976 by Lindstrom [2]. The term microscopic colitis was used by Read *et al*[3] in a 1980 publication describing a series of patients with chronic diarrhea of unknown origin. While initially considered uncommon, population-based studies have shown a rising incidence that may have started to plateau[4-6].

Microscopic colitis is now a frequent cause of chronic diarrhea, particularly in older adults. In some regions, the incidence of microscopic colitis exceeds Crohn's disease and ulcerative colitis[7]. Despite an increasing burden of disease, the etiology of microscopic colitis is not known. Prior studies implicated a range of medications including proton pump inhibitors (PPIs), nonsteroidal anti-inflammatory drugs (NSAIDs), statins, and beta blockers[8]. Cigarette smoking has also been implicated[9, 10]. The condition has been reported to be more common in patients with a number of auto-immune diseases[11].

There is currently limited information that obesity might be inversely associated with microscopic colitis[12,13]. We conducted a case-control study among a population of patients scheduled for colonoscopy due to chronic diarrhea in order to assess whether obesity and hormonal factors might be associated with microscopic colitis.

MATERIALS AND METHODS

Briefly, we identified male and female patients between April 1, 2015 and December 22, 2020 who were referred for outpatient colonoscopy for diarrhea. We excluded patients with a prior history of Crohn's disease and ulcerative colitis. Potential participants were mailed information about the study in advance of their procedure. On the day of their exam, eligibility was verified by a research assistant who obtained informed consent for participation. To be eligible for the study, patients had to report a Bristol Stool Form type 5, 6, or 7 (mushy, loose, watery) during the week prior to their colonoscopy regardless of the number of stools[14]. We recruited patients from each of the 3 endoscopy units at the University of North Carolina Chapel Hill. If the research assistant was not available for consent at the time of the procedure, the patient was later contacted to verify eligibility and obtain consent. We also queried the hospital pathology database every month and contacted patients with biopsy proven microscopic colitis who were not identified prior to their colonoscopy. This group included patients who were referred for colonoscopy for other reasons (generally screening) but reported diarrhea and had colon biopsies taken during the colonoscopy to assess for microscopic colitis. In sensitivity analyses, the patients identified retrospectively from pathology were excluded.

Patients with signs of gross inflammation on colonoscopy were excluded. Patients with subtle or isolated mucosal abnormalities were not excluded. Patients with non-lymphocytic colitis on biopsies were also excluded. A research pathologist (JTW) who was not aware of the clinical diagnosis reviewed the slides for all enrolled study subjects. Cases were patients with microscopic colitis on biopsy defined by increased number of intraepithelial lymphocytes. Additional features included increased lamina propria chronic inflammation, with minimal crypt distortion or active cryptitis. Collagenous colitis was defined by a thickened subepithelial collagen band. Slides were initially reviewed by a clinical pathologist. The slides were then re-read by the study pathologist. When there was a disagreement between the clinical pathologist and the research pathologist, the research pathologist re-read the slides. In addition, a 20% sample of slides were resubmitted to the research pathologist. After excluding indeterminate colitis, there was a 100% match between the initial and final reading by the research pathologist. Controls were patients with normal pathology. Patients with indeterminate microscopic colitis based on a sparse number of lymphocytes were excluded to avoid possible misclassification and because there were too few for separate analysis.

After the colonoscopy, all participants completed a 30 to 40-minute structured telephone interview or self-completed the same questionnaire using an internet-based form. The telephone interviewer verified eligibility, including the diarrhea criteria, for patients who were identified from pathology or who were missed in the endoscopy unit. Participants self-reported demographics, body weight, height, medical history including over-the-counter and prescription medications, reproductive history, bowel habits, and gastrointestinal symptoms. The reproductive history for women included questions about age at first menses, oral contraceptive use, gravidity, parity, and if postmenopausal, age at and type of menopause, and menopause hormone therapy use. All exogenous hormone questions included age at initiation, duration of use, and use in the last year, but not type of hormone or dose. BMI was calculated from self-reported weight in kilograms divided by height in meters squared (kg/m^2). BMI was categorized using Centers for Disease Control criteria: BMI < 25 kg/m^2 (under- or healthy weight), BMI 25.0 < 30 kg/m^2 (overweight), BMI > 30 kg/m^2 (obese).

Data analysis was conducted using Stata 17.0 (Stata Corp. College Station, TX). The analysis was reviewed by a biostatistician (JAG). Variables were examined one-by-one in bivariate analyses using chi square tests for categorical variables and Student t-tests for continuous variables. Multivariable logistic regression models were used to calculate adjusted odds ratios and 95% confidence intervals adjusted for age, educational status and BMI. Smoking was not included in models because smoking was not independently associated with microscopic after adjusting for education. We have previously examined the association between medications thought to be

associated with microscopic colitis (PPI, statins, SSRI, NSAIDs)[15]. There was no association in our study so those drugs were not included in models. Multivariable logistic models also included terms for reproductive factors including age at first live birth, number of live births and age of menarche. The model terms were informed by review of the relevant literature and directed acyclic graphs (DAGs)[16]. For analyses of menopause, the reference group was the most common age of natural menopause, age 45-54. Missing data were not imputed.

The study was approved by the University of North Carolina Office of Human Research Ethics. All patients gave informed consent.

RESULTS

Patients were enrolled in the study between April 1, 2015 and December 22, 2020. Among the 1008 patients who were referred for colonoscopy for diarrhea, 176 cancelled their colonoscopy, 161 were ineligible, 99 were missed in the endoscopy unit and not subsequently recruited, and 196 refused. After excluding indeterminate colitis ($n = 14$), there were 362 who serve as the basis of this report. There were 110 microscopic colitis cases (including 34 identified from pathology reports) and 252 controls. Interviews were completed by phone by 84% of subjects and Internet for the remainder.

Table 1 shows characteristics of the study population. The cases were older than controls: case mean age 63.2 (standard deviation (SD) 12.7, interquartile range 53-73) *vs* control mean age 54.5 (SD 11.8, interquartile range 45-64). Cases were more likely than controls to be white (96.2% *vs* 85.7%). As a group, the study subjects were very well educated, but cases were more likely to have a college degree or have attended graduate school, 66.0% *vs* 44.3%. Cases were less likely to be current smokers, 11.3% *vs* 21.0%. There was a strong correlation between smoking and education, with better educated patients substantially less likely to smoke (not shown). There was no difference between cases and controls for marital status, race, or smoking after adjustment.

Overall, mean BMI was lower in cases (BMI 25.7 kg/m² (SD 6.4)) than controls (BMI 29.5 kg/m² (SD 7.2)). As shown in Table 2, the risk for microscopic colitis was lower for BMI 25-30 kg/m² (OR 0.71, 95%CI: 0.40-1.25) and BMI > 30 kg/m² (OR 0.31, 95%CI: 0.17-0.55) compared to under- or healthy weight (BMI < 25 kg/m²) as the reference. Similar results were seen in analyses adjusted for age and education. To determine whether the results were comparable for men and women, we stratified by sex. The results for women were similar to the overall results with lower risk for obese women. The results for men were null, but the number of men was small making estimates unstable with wide confidence intervals around risk estimates. Patients with microscopic colitis were more likely to report weight loss following the onset of diarrhea than controls: 65.3% cases *vs* 42.5% controls, $p < 0.001$. Because current BMI could be misclassified due to weight loss following the onset of diarrhea, we stratified on weight loss. The results were similar in the weight loss and the no weight loss strata. We conducted analyses separately for lymphocytic colitis and collagenous colitis and the results were similar to the overall.

All of the patients in our study had diarrhea. We asked patients if they had ever been told by a physician that they had irritable bowel syndrome (IBS). Not surprisingly the cases were less likely to have a history of IBS, odds ratio 0.40, 95%CI: 0.20 – 0.78). When we stratified by IBS, patients in the highest BMI category were less likely to have microscopic colitis in the non-IBS stratum, aOR 0.38 (95%CI: 0.18-0.79) an estimate similar to the overall estimate in cases and controls. We compared the BMI in patients with IBS stratified by microscopic colitis status. In the microscopic colitis cases, the mean BMI was not different in the IBS group (24.6 kg/m² (SD 7.2)) and the non-IBS group (25.7 kg/m² (SD 6.4), $P = 0.55$). Similarly, the mean BMI was not different among the controls with IBS (30.3 kg/m² (SD 6.6)) compared to non-IBS controls (29.1 kg/m² (SD 7.2), $P = -0.27$)).

Because the risk for microscopic colitis was lower in obese women than men (recognizing small numbers of men), we examined potential hormonal risk factors in women. Reproductive factors are shown in Table 3. The table shows crude odds ratios and odds ratios adjusted for age, education and BMI (model 1) and age, education, BMI, number of live births and age at menarche (model 2). Age at menarche, parity, number of live births and age at first live birth were not different in cases and controls. Use of oral contraceptive pills was inversely associated with microscopic colitis in crude (OR 0.41, 95%CI: 0.22-0.79), adjusted (aOR 0.38, 95%CI: 0.17-0.84), and multiply

Table 1 Characteristics of the study population

	Cases, <i>n</i> = 110		Controls, <i>n</i> = 252	
	<i>n</i>	Percent	<i>n</i>	Percent
Age ^a				
mean	63.2	12.7	54.5	11.8
Race ^b				
White	102	96.2	186	85.7
Non-White	4	3.8	31	14.3
Sex ^a				
Female	94	86.2	176	69.8
Male	15	13.8	76	30.2
Marital status				
Married	75	70.8	146	66.7
Not married	31	29.3	73	33.3
Education ^a				
Less than college	36	34.0	122	55.7
College or postgrad	70	66.0	97	44.3
Cigarette smoking ^c				
Never smoker	48	45.3	107	48.9
Former smoker	46	43.4	66	30.1
Current smoker	12	11.3	46	21.0
Irritable bowel syndrome ^b				
Yes	14	13.6	60	28.0
No	89	86.4	154	72.0

^a*P* < 0.001.^b*P* < 0.005.^c*P* < 0.05.

adjusted analyses (aOR 0.20, 95%CI: 0.08-0.52). The results were the same when cases identified by pathology were excluded. The results were also similar for lymphocytic and collagenous colitis.

Menopausal factors are shown in Table 4. The percent of women who were postmenopausal was higher in the cases in crude analyses, but that is because they were older. The difference was absent in the adjusted model. Cases were more likely to have ever-used menopausal hormone hormones in the crude analysis OR 2.79, 95%CI: 1.44-5.41). After adjusting for age, education and BMI the risk estimate was lower (aOR 1.63, 95%CI: 0.73-3.62).

DISCUSSION

We found a striking difference in the risk for microscopic colitis with BMI, with a strong inverse association with obesity in women. Women with microscopic colitis were substantially less likely to be obese. There was no apparent effect of BMI on risk for microscopic colitis in men, although the number of men in our study was small. Given the sex differences, we also looked for possible reproductive or hormonal associations. We found a strong inverse association of microscopic colitis with ever use of oral contraceptives. In contrast to most prior studies, we enrolled patients who were referred for colonoscopy for diarrhea. At the time of the referral, the status as a microscopic colitis case or control was not known. All participants had similar symptoms, access to care, colonoscopy and biopsies.

Table 2 Body mass index and risk of microscopic colitis

	Cases		Controls		Crude	Adjusted ¹
	n = 101		n = 238			
BMI	n	%	n	%	OR (95%CI)	aOR (95%CI)
Overall						
< 25	50	49.5	73	30.7	Ref.	Ref.
25 < 30	29	28.7	60	25.2	0.71 (0.40-1.25)	0.70 (0.37-1.31)
≥ 30	22	21.8	105	44.1	0.31 (0.17-0.55)	0.35 (0.18-0.66)
Women						
< 25	47	53.4	47	28.7	Ref.	Ref.
25 -30	24	27.3	34	20.7	0.71 (0.36-1.37)	0.67 (0.32-1.40)
≥ 30	17	19.3	83	50.6	0.20 (0.10-0.40)	0.21 (0.10-0.45)
Men						
< 25	3	23.1	26	35.1	Ref.	Ref.
25 -30	5	38.5	26	35.1	1.67 (0.36-7.71)	2.22 (0.41-12.05)
≥ 30	5	38.5	22	29.7	1.97 (0.42-9.19)	2.92 (0.52-16.22)
Lost weight						
< 25	34	60.7	32	44.4	Ref.	Ref.
25 -30	13	23.2	17	23.6	0.72 (0.30-1.71)	0.89 (0.35-2.22)
≥ 30	9	16.1	23	31.9	0.37 (0.15-0.91)	0.49 (0.19-1.28)
No weight loss						
< 25	10	31.3	20	19.4	Ref.	Ref.
25 -30	13	40.6	30	29.1	0.87 (0.31-2.36)	0.64 (0.20-2.04)
≥ 30	9	28.1	53	51.5	0.33 (0.12-0.96)	0.33 (0.10-1.11)
IBS						
< 25	9	69.2	15	25.4	Ref.	Ref.
25-30	2	15.4	15	25.4	0.22 (0.04-1.21)	0.26 (0.04-1.50)
≥ 30	2	15.4	29	49.2	0.11 (0.02-0.60)	0.13 (0.02-0.76)
No IBS						
< 25	39	47.6	47	32.6	Ref.	Ref.
25 -30	26	31.7	37	25.7	0.85 (0.44-1.63)	0.78 (0.39-1.58)
≥ 30	17	20.7	60	41.7	0.34 (0.17-0.68)	0.38 (0.18-0.79)

¹Adjusted for age and education. BMI: Body mass index; IBS: Irritable bowel syndrome.

Although BMI is an important risk factor for a number of diseases, there is surprisingly little information on the association between BMI and microscopic colitis. In a study using population controls, Larsen *et al*[17] reported data on 135 microscopic colitis who were compared to 27960 participants in the Malmo Diet and Cancer Study. There was no difference between the groups with respect to BMI. Similar to our study, Pascua *et al*[18] included 259 diarrhea controls in a small study with 26 microscopic colitis patients. There was no difference in BMI. Another small study was designed to examine the microbiome in 20 patients with microscopic colitis, 20 age- and sex-matched healthy controls, and 20 patients with functional diarrhea according to Rome IV criteria[19]. The BMI was 24.7 (SD 3.5) in microscopic colitis patients, 28.2 (SD 6.9) in healthy controls, and 27.9 (5.5) in the patients with chronic diarrhea. No statistics were reported in the paper, but based on the sample size and the estimates, the difference was significant for healthy controls ($P = 0.05$) and for diarrhea controls ($P =$

Table 3 Reproductive factors and risk of microscopic colitis in women

	Cases		Controls				
	n = 94		n = 176		Crude	Model 1 ¹	Model 2 ²
	n	%	n	%	OR (95%CI)	aOR (95%CI)	aOR (95%CI)
Age of menarche							
≤ 11	18	20.5	46	30.3	Ref.	Ref.	Ref.
12	24	27.3	36	23.7	1.70 (0.80-3.61)	1.30 (0.53-3.17)	1.41 0.52-3.83)
13	23	26.1	38	25.0	1.55 (0.73-3.28)	0.76 (0.31-1.85)	0.54 (0.20-1.43)
≥ 14	23	26.1	32	21.1	1.84 (0.86-3.94)	0.90 (0.36-2.28)	0.85 (0.30-2.42)
Parity							
Nulliparous	15	16.5	29	19.0	Ref.	Ref.	Ref. ³
Parous	76	83.5	124	81.1	1.04 (0.88-1.24)	1.02 (0.83-1.25)	1.00 (0.81-1.23)
Number of live births							
None	15	16.5	29	19.0	Ref.	Ref.	Ref. ³
1	13	14.3	20	13.1	1.26 (0.49-3.20)	1.16 (0.39-3.48)	1.19 (0.40-3.60)
2	42	46.2	60	39.2	1.35 (0.65-2.83)	1.20 (0.50-2.89)	1.15 (0.47-2.81)
3 or more	21	23.1	44	28.8	0.92 (0.41-2.08)	0.78 (0.28-2.16)	0.83-0.30-2.35)
Age of first live birth (among parous women)							
≤ 19	13	17.1	32	25.8	Ref.	Ref.	Ref.
20-23	12	15.8	42	33.9	0.70 (0.28-1.75)	0.24 (0.07-0.82)	0.23 (0.07-0.85)
24-29	26	34.2	27	21.8	2.37 (1.02-5.49)	0.76 (0.24-2.43)	0.78 (0.23-2.63)
30+	25	32.9	23	18.6	2.68 (1.13-6.31)	1.07 (0.32-3.58)	1.02 (0.28-3.68)
Oral contraceptives							
No	27	29.7	23	15.0	Ref.	Ref.	Ref.
Yes	64	70.3	130	85.0	0.42 (0.22-0.79)	0.38 (0.17-0.84)	0.20 (0.08-0.52)

¹Model 1 Adjusted for age, education and body mass index (BMI).²Model 2 adjusted for age, education, BMI, age first live birth, number of live births, age of menarche.³Omitted age of first live birth from model because of collinearity.

0.03). Roth *et al*[20] identified microscopic colitis cases from pathology records from 2002 – 2010 from the Skåne University Hospital, Malmö, with controls selected from a population-based study of breast cancer. The BMI in cases was 24.84 kg/m² and controls 24.88 kg/m², $P = 0.451$. The cases and controls were not recruited contemporaneously.

Cotter *et al*[13] sought to develop a scoring system to predict microscopic colitis among patients presenting with diarrhea. In a derivation cohort of 617 patients, BMI < 30 kg/m² was associated with an increased risk of microscopic colitis, OR 2.15 (95%CI: 1.19-3.88). Weight loss has been shown to be associated with MC in publications by the same authors[21,22], and it is not clear whether weight loss might have led to misclassification of BMI category. Liu *et al*[12] used the two Nurses' Health Study cohorts to identify 244 cases of self-reported microscopic colitis with 4.2 million person-years of observation. Compared to the women in the lowest BMI category, BMI < 18.5 kg/m², those with a BMI > 30 had an adjusted hazard ratio of 0.50 (95%CI: 0.32-0.79). The p for trend was < 0.001. Weight gain since early adulthood was also associated with reduced risk of microscopic colitis. The results were seen in both Nurses cohorts.

Cigarette smokers weigh, on average, 4–5 kg less than nonsmokers and are less likely to be overweight or obese[23]. Cigarette smoking has been associated linked with microscopic colitis in a meta-analysis[9]. In our study, however, current smoking was more common in the controls (who were heavier) and smoking was not associated with microscopic colitis after controlling for education.

Table 4 Menopausal factors and risk of microscopic colitis in women

	Cases		Controls			
	n = 94		n = 176		Crude	Adjusted
	n	%	n	%	OR (95%CI)	OR (95%CI) [†]
Menopausal status						
Pre-menopausal	13	14.4	40	26.1	Ref.	Ref.
Post-menopausal	77	85.6	113	73.9	2.10 (1.05-4.18)	1.20 (0.45-3.20)
Age at menopause						
< 45	17	24.3	49	45.8	0.37 (0.19-0.74)	0.64 (0.28-1.46)
45-54	43	61.4	46	43.0	Ref.	Ref.
55+	10	14.3	12	11.2	0.89 (0.35-2.27)	0.79 (0.28-2.22)
Menopausal type						
Surgical	31	40.3	70	62.0	Ref.	Ref.
Natural menopause	46	59.7	43	38.1	0.41 (0.23-0.75)	0.76 (0.37-1.54)
Menopausal hormones ²						
No	46	60.5	90	81.1	Ref.	Ref.
Ever	30	39.5	21	18.9	2.80 (1.44-5.41)	1.63 (0.73-3.62)
Years Postmenopausal hormones ²						
None	46	60.5	90	81.8	Ref.	Ref.
1-7 yr	15	19.7	11	10	2.67 (1.13-6.28)	1.65 (0.59-4.65)
9+ yr	15	19.7	9	8.2	3.26 (1.33-8.02)	1.68 (0.60-4.73)

¹Adjusted for age, education and body mass index.²Among women after menopause.

The controls in our study had diarrhea. If the diarrhea controls had a condition associated with obesity, that could potentially explain the findings. Many of the diarrhea patients who did not have microscopic colitis probably had irritable bowel syndrome. In a stratified analysis, the inverse association with obesity was particularly strong in the IBS strata (both cases and controls had a history of IBS). It is not clear that patients with IBS are more likely to be obese. A comprehensive review has not shown BMI differences in patients with irritable bowel syndrome[24]. In our study the controls with IBS did not have a higher BMI than the controls without IBS.

The mechanism by which increased body weight might be inversely associated with microscopic colitis in our study and others is uncertain. Men are at substantially reduced risk of microscopic colitis than women[4]. Perhaps the reduced risk is due to a protective effect of androgens. Obesity has been associated with increased levels of androgens[25,26]. Obesity has been linked with change in the gut microbiome[27] which has, in turn, been linked with microscopic colitis[19,28,29]. The gut microbiota can metabolize androgens and estrogens[30].

Despite the marked sex discrepancy in microscopic colitis, the literature on reproductive and hormonal factors is very limited. Burke *et al* used data from the Nurses' Health Study cohorts[31]. Similar to our results, the authors found no association with age of menarche, parity, age of first live birth or age of menopause. They found an increased risk for postmenopausal hormones. Verhaegh *et al*[32] reported that hormonal factors were not associated with microscopic colitis in multivariable analysis, although number of cases might not have been large enough to detect small differences between populations.

We found that ever-use of oral contraceptive pills was associated with a reduced risk of microscopic colitis in crude and adjusted analyses. In contrast to our study, Burke *et al*[31] reported that ever-use of oral contraceptives was associated with an increased risk of microscopic colitis based on data from the two Nurses' Health Study cohorts. There was a large difference in oral contraceptive use in the two cohorts - 45% in the Nurses' Health Study (NHS) and 85% in Nurses' Health Study II (NHSII). Oral

contraceptive use was not queried after 1984 in NHS (almost 40 years ago), or after 2009 in NHSII. The elevated risk was only statistically significant in the earlier cohort. There has been a temporal change in the hormone concentration of oral contraceptive pills, and the different results between our study and the Nurses' cohort study might be due to different times of enrollment. OCPs generally contain a mix of estrogen (usually estradiol) and a progestin. The estrogen dose has decreased from over 100 µg when first introduced in the 1960 to 20-30 µg or less now. Progestin-only contraceptives are also now available. These changes mean studies may not be comparable if they were performed at different times.

The mechanism behind the observed associations of menopausal hormones and oral contraceptives with microscopic colitis are unknown although there are some possibilities to consider. Estrogen and progesterone receptors are expressed in the gut, and sex steroids have been shown to influence colonic transit time, chloride secretion and intestinal permeability[33]. Autoimmune diseases are more common in women than men, possibly due to hormonal factors[34]. Hormonal contraceptives have effects on the immune system and have been linked with a number of different autoimmune diseases[35]. Microscopic colitis has been regarded as an autoimmune disease, perhaps because of similarities to celiac disease[36]. In a genome-wide association study using the UK Biobank, there was an association with single nucleotide polymorphisms on the MHC 8.1 haplotype, supporting an immune component to the pathogenesis of microscopic colitis[37]. We did not find autoimmune disease was over-represented in our microscopic colitis cases (unpublished data). The gut microbiome is involved in the metabolism, excretion and circulation of sex hormones[30]. The effect of menopausal hormones and oral contraceptives on microscopic colitis could be mediated by gut microbes. Gut microbes could metabolize sex steroids or exogenous steroids and alter the gut environment.

Our study had some important strengths. The patients were drawn from the same referral area and had similar access to and receipt of care. All of the patients had diarrhea. Other studies have used community[38], population[39], or disease controls [40]. A single experienced gastrointestinal pathologist reviewed all of the slides to classify patients as microscopic colitis cases or normal controls. The study included men and women. Detailed information was obtained from study participants using structured interviews.

A limitation of the study was the small size, particularly for men. Microscopic colitis is an uncommon disease and most reports in the literature are hampered by small numbers. Many of the patients referred for colonoscopy were either not eligible, cancelled their appointments or refused to participate. Nonresponse, along with the selected nature of the study population, may affect generalizability but should not lead to bias. Exposures were determined by self-report which is common in case-control studies. Recall of past exposures may be inaccurate, but we would not expect the recall for cases and controls to be differential as all of the patients were enrolled in the study because of diarrhea. Cases were older than controls. We adjusted for age in all models and we performed sensitivity analyses with similar results. Lymphocytic colitis and collagenous colitis are considered to be histologic subtypes of the same disease[41]. We combined the two entities to improve study power. In exploratory analyses we found similar results when we examine each type separately. The study was conducted in a developed country. Geographic variations in the incidence of microscopic colitis have been reported but there have been a limited number of direct comparative studies[1]. There are few studies from developing countries[42].

Microscopic colitis, first described in 1976, is a relatively new disease. With any new disease there is the presumption that an environmental factor, as opposed to a genetic factor, is responsible. Obesity has increased in the US since the 1980[43]. The incidence of microscopic colitis has also been increasing in the US [44]. The fact that we and others have found lower risk of microscopic colitis with obesity suggests that obesity must interact with some other factor such as the microbiome to mediate risk. Given the difference in distribution in microscopic colitis by sex, exogenous hormones in the form of birth control pills and postmenopausal hormones are naturally of interest. In this study we found that postmenopausal hormones were modestly associated with an increased risk of microscopic colitis and oral contraceptives with decreased risk.

As the population ages, the number of patients with microscopic colitis is likely to increase. Identifying factors associated with risk for microscopic colitis is an important first step developing hypotheses about etiology.

CONCLUSION

Compared to controls also seen for diarrhea, microscopic colitis cases were less likely to be obese. Mechanisms are unknown but could involve hormonal effects of obesity or the gut microbiome.

ARTICLE HIGHLIGHTS

Research background

There is limited information about risk factors for microscopic colitis, a leading cause of chronic watery diarrhea.

Research motivation

We hypothesized that obesity might be associated with microscopic colitis.

Research objectives

To compare patients with microscopic colitis to patients with chronic diarrhea to learn more about associations with obesity and hormones.

Research methods

We conducted a case-control study among patients who were referred to a single academic medical center for chronic diarrhea. The biopsies were reviewed by a research pathologist and classified as microscopic colitis cases or diarrhea controls. We used logistic regression to estimate odds ratios and 95% confidence intervals.

Research results

Cases with microscopic colitis had a lower body mass index than controls in adjusted models. Although patients with microscopic colitis reported that they lost more weight following the onset of diarrhea, the associations with BMI persisted in analyses stratified by weight loss. Oral contraceptives were inversely associated with microscopic colitis.

Research conclusions

Microscopic colitis cases were less likely to be obese than diarrhea controls. While the mechanism behind the association is not known, it could involve hormonal effects of obesity or the gut microbiome.

Research perspectives

Additional research is needed to understand the association between obesity and microscopic colitis.

REFERENCES

- 1 Miehke S, Guagnozzi D, Zabana Y, Tontini GE, Kanstrup Fiehn AM, Wildt S, Bohr J, Bonderup O, Bouma G, D'Amato M, Heiberg Engel PJ, Fernandez-Banares F, Macaigne G, Hjortswang H, Hultgren-Hornquist E, Koulaouzidis A, Kupcinkas J, Landolfi S, Latella G, Lucendo A, Lyutakov I, Madisch A, Magro F, Marlicz W, Mihaly E, Munck LK, Ostvik AE, Patai AV, Penchev P, Skonieczna-Zydecka K, Verhaegh B, Munch A. European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. *United European Gastroenterol J* 2021
- 2 Lindstrom CG. Collagenous colitis' with watery diarrhoea--a new entity? *Pathol Eur* 1976; **11**: 87-89
- 3 Read NW, Krejs GJ, Read MG, Santa Ana CA, Morawski SG, Fordtran JS. Chronic diarrhea of unknown origin. *Gastroenterology* 1980; **78**: 264-271
- 4 Weimers P, Ankersen DV, Lophaven S, Bonderup OK, Münch A, Løkkegaard ECL, Burisch J, Munkholm P. Incidence and prevalence of microscopic colitis between 2001 and 2016: A Danish nationwide cohort study. *J Crohns Colitis* 2020
- 5 Bergman D, Clements MS, Khalili H, Agréus L, Hultcrantz R, Ludvigsson JF. A nationwide cohort study of the incidence of microscopic colitis in Sweden. *Aliment Pharmacol Ther* 2019; **49**: 1395-1400
- 6 Davidson S, Sjöberg K, Engel PJH, Lo Rinc E, Fiehn AK, Vigren L, Munck LK. Microscopic colitis in Denmark and Sweden: incidence, putative risk factors, histological assessment and endoscopic activity. *Scand J Gastroenterol* 2018; **53**: 818-824

- 7 **Gentile NM**, Yen EF. The Incidence of Microscopic Colitis: Microscopic No More. *Dig Dis Sci* 2017; **62**: 1394-1395
- 8 **Park T**, Cave D, Marshall C. Microscopic colitis: A review of etiology, treatment and refractory disease. *World J Gastroenterol* 2015; **21**: 8804-8810
- 9 **Jaruvongvanich V**, Poonsombudlert K, Ungprasert P. Smoking and Risk of Microscopic Colitis: A Systematic Review and Meta-analysis. *Inflamm Bowel Dis* 2019; **25**: 672-678
- 10 **Burke KE**, Ananthakrishnan AN, Lochhead P, Olen O, Ludvigsson JF, Richter JM, Chan AT, Khalili H. Smoking is Associated with an Increased Risk of Microscopic Colitis: Results From Two Large Prospective Cohort Studies of US Women. *J Crohns Colitis* 2018; **12**: 559-567
- 11 **Vigren L**, Tysk C, Ström M, Kilander AF, Hjortswang H, Bohr J, Benoni C, Larson L, Sjöberg K. Celiac disease and other autoimmune diseases in patients with collagenous colitis. *Scand J Gastroenterol* 2013; **48**: 944-950
- 12 **Liu PH**, Burke KE, Ananthakrishnan AN, Lochhead P, Olen O, Ludvigsson JF, Richter JM, Chan AT, Khalili H. Obesity and Weight Gain Since Early Adulthood Are Associated With a Lower Risk of Microscopic Colitis. *Clin Gastroenterol Hepatol* 2019; **17**: 2523-2532.e1
- 13 **Cotter TG**, Binder M, Harper EP, Smyrk TC, Pardi DS. Optimization of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea. *J Clin Gastroenterol* 2017; **51**: 228-234
- 14 **Lewis SJ**, Heaton KW. Stool form scale as a useful guide to intestinal transit time. *Scand J Gastroenterol* 1997; **32**: 920-924
- 15 **Sandler RS**, Keku TO, Woosley JT, Galanko JA, Peery AF. Medication use and microscopic colitis. *Aliment Pharmacol Ther* 2021; **54**: 1193-1201
- 16 **Greenland S**, Pearl J, Robins JM. Causal diagrams for epidemiologic research. *Epidemiology* 1999; **10**: 37-48
- 17 **Larsson JK**, Sonestedt E, Ohlsson B, Manjer J, Sjöberg K. The association between the intake of specific dietary components and lifestyle factors and microscopic colitis. *Eur J Clin Nutr* 2016; **70**: 1309-1317
- 18 **Pascua MF**, Kedia P, Weiner MG, Holmes J, Ellenberg J, Lewis JD. Microscopic colitis and Medication Use. *Clin Med Insights Gastroenterol* 2010; **2010**: 11-19
- 19 **Morgan DM**, Cao Y, Miller K, McGoldrick J, Bellavance D, Chin SM, Halvorsen S, Maxner B, Richter JM, Sassi S, Burke KE, Yarze JC, Ludvigsson JF, Staller K, Chung DC, Khalili H. Microscopic Colitis Is Characterized by Intestinal Dysbiosis. *Clin Gastroenterol Hepatol* 2020; **18**: 984-986
- 20 **Roth B**, Manjer J, Ohlsson B. Microscopic colitis and reproductive factors related to exposure to estrogens and progesterone. *Drug Target Insights* 2013; **7**: 53-62
- 21 **Kane JS**, Rotimi O, Everett SM, Samji S, Michelotti F, Ford AC. Development and validation of a scoring system to identify patients with microscopic colitis. *Clin Gastroenterol Hepatol* 2015; **13**: 1125-1131
- 22 **Kane JS**, Sood R, Law GR, Gracie DJ, To N, Gold MJ, Ford AC. Validation and modification of a diagnostic scoring system to predict microscopic colitis. *Scand J Gastroenterol* 2016; **51**: 1206-1212
- 23 **Audrain-McGovern J**, Benowitz NL. Cigarette smoking, nicotine, and body weight. *Clin Pharmacol Ther* 2011; **90**: 164-168
- 24 **Pickett-Blakely O**. Obesity and irritable bowel syndrome: a comprehensive review. *Gastroenterol Hepatol* 2014; **10**: 411-416
- 25 **Pasquali R**. Obesity and androgens: facts and perspectives. *Fertil Steril* 2006; **85**: 1319-1340
- 26 **Pasquali R**, Oriolo C. Obesity and Androgens in Women. *Front Horm Res* 2019; **53**: 120-134
- 27 **Maruvada P**, Leone V, Kaplan LM, Chang EB. The Human Microbiome and Obesity: Moving beyond Associations. *Cell Host Microbe* 2017; **22**: 589-599
- 28 **Hertz S**, Durack J, Kirk KF, Nielsen HL, Lin DL, Fadros D, Lynch K, Piceno Y, Thorlacius-Ussing O, Nielsen H, Lynch SV. Microscopic Colitis Patients Possess a Perturbed and Inflammatory Gut Microbiota. *Dig Dis Sci* 2021
- 29 **Rindom Krogsgaard L**, Kristian Munck L, Bytzer P, Wildt S. An altered composition of the microbiome in microscopic colitis is driven towards the composition in healthy controls by treatment with budesonide. *Scand J Gastroenterol* 2019; **54**: 446-452
- 30 **Yoon K**, Kim N. Roles of Sex Hormones and Gender in the Gut Microbiota. *J Neurogastroenterol Motil* 2021; **27**: 314-325
- 31 **Burke KE**, Ananthakrishnan AN, Lochhead P, Liu PH, Olen O, Ludvigsson JF, Richter JM, Tworoger SS, Chan AT, Khalili H. Identification of Menopausal and Reproductive Risk Factors for Microscopic Colitis-Results From the Nurses' Health Study. *Gastroenterology* 2018; **155**: 1764-1775.e2
- 32 **Verhaegh BPM**, Pierik MJ, Goudkade D, Cuijpers YSMT, Masclee AAM, Jonkers DMAE. Early Life Exposure, Lifestyle, and Comorbidity as Risk Factors for Microscopic Colitis: A Case-Control Study. *Inflamm Bowel Dis* 2017; **23**: 1040-1046
- 33 **Braniste V**, Leveque M, Buisson-Brenac C, Bueno L, Fioramonti J, Houdeau E. Oestradiol decreases colonic permeability through oestrogen receptor beta-mediated up-regulation of occludin and junctional adhesion molecule-A in epithelial cells. *J Physiol* 2009; **587**: 3317-3328
- 34 **Angum F**, Khan T, Kaler J, Siddiqui L, Hussain A. The Prevalence of Autoimmune Disorders in Women: A Narrative Review. *Cureus* 2020; **12**: e8094

- 35 **Williams WV.** Hormonal contraception and the development of autoimmunity: A review of the literature. *Linacre Q* 2017; **84**: 275-295
- 36 **Sonnenberg A,** Turner KO, Genta RM. Associations of Microscopic Colitis With Other Lymphocytic Disorders of the Gastrointestinal Tract. *Clin Gastroenterol Hepatol* 2018; **16**: 1762-1767
- 37 **Green HD,** Beaumont RN, Thomas A, Hamilton B, Wood AR, Sharp S, Jones SE, Tyrrell J, Walker G, Goodhand J, Kennedy NA, Ahmad T, Weedon MN. Genome-Wide Association Study of Microscopic Colitis in the UK Biobank Confirms Immune-Related Pathogenesis. *J Crohns Colitis* 2019; **13**: 1578-1582
- 38 **Maslee GM,** Coloma PM, Kuipers EJ, Sturkenboom MC. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. *Am J Gastroenterol* 2015; **110**: 749-759
- 39 **Gentile NM,** Khanna S, Loftus EV, Jr. , Smyrk TC, Tremaine WJ, Harmsen WS, Zinsmeister AR, Kammer PP, Pardi DS. The epidemiology of microscopic colitis in Olmsted County from 2002 to 2010: a population-based study. *Clin Gastroenterol Hepatol* 2014; **12**: 838-842
- 40 **Fernández-Bañares F,** de Sousa MR, Salas A, Beltrán B, Piqueras M, Iglesias E, Gisbert JP, Lobo B, Puig-Divi V, García-Planella E, Ordás I, Andreu M, Calvo M, Montoro M, Esteve M, Viver JM; RECOMINA Project, GETECCU Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa. Epidemiological risk factors in microscopic colitis: a prospective case-control study. *Inflamm Bowel Dis* 2013; **19**: 411-417
- 41 **Rasmussen MA,** Munck LK. Systematic review: are lymphocytic colitis and collagenous colitis two subtypes of the same disease - microscopic colitis? *Aliment Pharmacol Ther* 2012; **36**: 79-90
- 42 **Gado AS,** Ebeid BA, El Hindawi AA, Akl MM, Axon AT. Prevalence of microscopic colitis in patients with chronic diarrhea in Egypt: a single-center study. *Saudi J Gastroenterol* 2011; **17**: 383-386
- 43 **Inoue Y,** Qin B, Poti J, Sokol R, Gordon-Larsen P. Epidemiology of Obesity in Adults: Latest Trends. *Curr Obes Rep* 2018; **7**: 276-288
- 44 **Tome J,** Sehgal K, Kamboj AK, Harmsen WS, Kammer PP, Loftus EV, Jr. , Tremaine WJ, Khanna S, Pardi DS. The Epidemiology of Microscopic Colitis in Olmsted County, Minnesota: Population-Based Study From 2011 to 2019. *Clin Gastroenterol Hepatol* 2021



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

